LC‐MS/MS Assay for Quantification of DA‐1241, a Novel GPR119 Agonist, in Animal and Human Plasma: Application to Preclinical Pharmacokinetic Studies
Journal of Mass Spectrometry · 2025
DOI: 10.1002/jms.5194 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Mass Spectrometry, 2025. Verfasst von Seung Jin Kim und 5 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy and Integrated Research Institute of Pharmaceutical Sciences, The Catholic University of Korea, Bucheon, South Korea. Hauptthemen laut MEDLINE: Tandem Mass Spectrometry, Receptors, G-Protein-Coupled. Die Arbeit nennt 16 Literaturangaben. Gefördert von: National Research Foundation of Korea, Dong-A ST Co. Ltd, The Catholic University of Korea.
Abstract (Originalsprache)
DA‐1241 is a novel GPR119 receptor agonist under development as a therapeutic candidate for metabolic dysfunction‐associated steatohepatitis. To enable precise quantification of DA‐1241 in mouse, rat, dog, and human plasma, a simple and highly sensitive LC‐MS/MS approach was designed and thoroughly evaluated. Plasma samples were processed using protein precipitation with acetonitrile, followed by chromatographic separation on a reverse‐phase C 18 column (3.0‐mm i.d. × 50 mm, 2.7 μm). Isocratic elution was achieved using a mobile phase composed of 1‐mM ammonium formate and 2‐mM formic acid in water and acetonitrile (13:87, v / v ) operated at a flow setting of 0.3 mL/min. Mass spectrometry analysis was conducted using an Agilent 6460 triple quadrupole system operated in multiple reaction monitoring with positive electrospray ionization. Ion transitions were m/z 472.1 → 135.9 for DA‐1241 and m/z 480.2 → 404.1 for DA‐1241‐d 8 (internal standard). The total chromatographic run time was 4.5 min. Linearity of the calibration curves was confirmed throughout the range of 1–10 000 ng/mL, with no carry‐over observed. Precision and accuracy for intra‐assay and interassay were within 14.3%, except at the lower limit of quantification, where values remained within 16.0%. The method met all the other validation criteria for matrix effect, recovery, and stability. The established method was successfully implemented on plasma protein binding assessments and preclinical pharmacokinetic studies of DA‐1241 after a single oral administration in mice, rats, and dogs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy and Integrated Research Institute of Pharmaceutical Sciences, The Catholic University of Korea, Bucheon, South Korea.
- Korea Institute of Radiological & Medical Sciences, Seoul, South Korea.
- Research Center, Dong-A ST Co. Ltd, Yongin, South Korea.
ORCID-Profile: Hee Eun Kang
Förderung
- National Research Foundation of Korea
- Dong-A ST Co. Ltd
- The Catholic University of Korea
- Catholic University of Korea
Zitieren
APA
Kim, S. J., Bang, W. S., Li, Z., Kwon, M. H., Lee, D. Y., & Kang, H. E. (2025). LC‐MS/MS Assay for Quantification of DA‐1241, a Novel GPR119 Agonist, in Animal and Human Plasma: Application to Preclinical Pharmacokinetic Studies. Journal of Mass Spectrometry. https://doi.org/10.1002/jms.5194
Vancouver
Kim SJ, Bang WS, Li Z, Kwon MH, Lee DY, Kang HE. LC‐MS/MS Assay for Quantification of DA‐1241, a Novel GPR119 Agonist, in Animal and Human Plasma: Application to Preclinical Pharmacokinetic Studies. Journal of Mass Spectrometry. 2025. doi:10.1002/jms.5194
BibTeX
@article{Kim2025,
author = {Kim, Seung Jin and Bang, Won Seok and Li, Zhengri and Kwon, Mi Hye and Lee, Dae Young and Kang, Hee Eun},
title = {LC‐MS/MS Assay for Quantification of DA‐1241, a Novel GPR119 Agonist, in Animal and Human Plasma: Application to Preclinical Pharmacokinetic Studies},
journal = {Journal of Mass Spectrometry},
year = {2025},
doi = {10.1002/jms.5194}
}
EUVIMED